Subscribe
Contact Us
About Us
Advertise
Home
News
News from MM&M
Off the Wire
Newsletters
PMD Profiles
Agency Creative Showcase
Publication Connection
PMD Marketplace
Careers
About Us
Additional Resources
MM&M
MM&M Jobs
MAHF
Voi Consulting
Advertise
Subscribe
Get Listed
Additional Resources
RSS
|
Login
|
Register
Biopharmaceutical
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
March 10, 2010
Affymax and Takeda will co-commercialize the product in the U.S.
CSL Behring Receives FDA Approval of Hizentra™
March 04, 2010
First 20 Percent Subcutaneous Immunoglobulin Therapy
FDA Approves Exalgo Extended-Release Tablets
March 02, 2010
CombinatoRx Achieves $40 Million Mil
Arena Pharmaceuticals Announces FDA Acceptance of Lorcaserin NDA for Filing
February 24, 2010
NDA is based on 18 clinical trials
Cephalon Exercises its Option to Acquire Ception Therapeutics
February 23, 2010
Ception Delivers Positive Results from a Phase II Study of CINQUIL in Adult Eosinophilic Asthma
Inspire Names Adrian Adams as President and Chief Executive Officer
February 19, 2010
Former President and CEO of Kos Pharmaceuticals, Inc. and Sepracor Inc.
Neuraltus Pharmaceuticals Names Andrew Gengos President and CEO
February 08, 2010
Mr. Gengos joins Neuraltus after more than seven years with Amgen
Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study
February 08, 2010
Daniel K. Spiegelman Joins Board of Directors
BioMarin to Acquire LEAD Therapeutics
February 04, 2010
Key Asset is LT-673
XenoPort Announces Horizant as Brand Name for XP13512
February 04, 2010
FDA review of NDA for Horizant is February 9, 2010
Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
February 03, 2010
Ronald A. Martell Named Chief Executive Officer
FDA Approves Xiaflex for Debilitating Hand Condition
February 03, 2010
First drug to treat Dupuytren's contracture
Enzon Completes Sale of Specialty Pharmaceutical Business
January 29, 2010
Enzon received $300 million in cash
Genocea Biosciences Appoints Paul Giannasca Vice President of Development
January 28, 2010
Former Vice President of Development at Acambis
Inspire Announces Results of Phase 3 PROLACRIA Trial for Dry Eye
January 21, 2010
Primary and Secondary Endpoints Not Met
Celgene Completes Acquisition of Gloucester Pharmaceuticals
January 15, 2010
Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 million
Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R)
January 13, 2010
Milestone Marks Swiss Company's Entrance into the U.S. Blood Coagulation Market
CombinatoRx Announces Senior Management Team Changes
January 06, 2010
Mark Corrigan, MD Appointed CEO
Biodel Submits VIAject® New Drug Application to FDA for Treatment of Diabetes
December 30, 2009
Vion Pharmaceuticals Announces FDA Conclusion
December 30, 2009
HOVON Trial As Designed Does Not Gain SPA Agreement
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
December 29, 2009
Significant reductions in cardiovascular and metabolic risk factors
Vical's Allovectin-7(R) Phase 3 Trial Receives Positive Review From Safety Monitoring Board
December 28, 2009
Allovectin-7(R) has been granted orphan drug designation
Ligand Completes Neurogen Acquisition
December 23, 2009
Ligand gains a fully funded partnership with Merck & Co.
Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
December 22, 2009
BLOOM-DM trial is planned as a supplement to the NDA
Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
December 21, 2009
Company Expects FDA Decision by End of First Quarter 2010
Access Pharmaceuticals Appoints Sales and Marketing Executive
December 15, 2009
Critical Step Toward U.S. Marketing Launch of Mugard
Adamis Pharmaceuticals Announces Signing of Definitive Merger Agreement
December 07, 2009
Adamis to acquire La Jolla Pharmaceutical Company
FDA Grants First Approval for a Product Derived from Pichia pastoris
December 07, 2009
First product for Dyax Corp.
AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
December 07, 2009
Study Z-036 did not reach its primary endpoint
Santarus Announces FDA Approval of Schering-Plough HealthCare Products' ZEGERID OTC
December 02, 2009
Santarus earns $20 million milestone
Latest News
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Lilly to Acquire European Rights to Pfizer Animal Health Assets
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Most Popular
Most Emailed
Most Recent
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
FDA Approves Exalgo Extended-Release Tablets
Astellas Pharma Inc. Commences Tender Offer to Acquire All Outstanding Shares of OSI Pharmaceuticals for $52 per Share in Cash
Transdel Pharmaceuticals Appoints Terry Nida as Chief Business Officer
Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
Astellas Pharma Inc. Offers to Acquire OSI Pharmaceuticals for $52.00 Per Share in Cash
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
FDA Advisory Committee Recommends Approval Of XIFAXAN® (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Lilly to Acquire European Rights to Pfizer Animal Health Assets
Alun Malone Joins Millennium Laboratories As New Business Development Executive
CSL Behring Receives FDA Approval of Hizentra™
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Lilly to Acquire European Rights to Pfizer Animal Health Assets
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Popular Topics
Acquisition
Agency
Animal Health
Biopharmaceutical
Biotech
Business
Clinical Management
Collaboration
Marketing & Communications
Medical Device
Medical Equipment
Merger
New Company
New Hire
New Hires
Personnel
Pharmaceutical
Pharmaceutical Marketplace
Pharmaceutical Products
Pipeline
Product Acquisition
Product Launch
Product Promotion
Regulatory
Research & Development